Investments
1Partners & Customers
10About Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Pharma (TYO: 4508) is a research-driven pharmaceutical company based in Japan, specializing in research, development, and marketing of globally competitive pharmaceutical products focused on the field of autoimmune disease, diabetes and kidney disease, and CNS disease.

Want to inform investors similar to Mitsubishi Tanabe Pharma about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Mitsubishi Tanabe Pharma News
Sep 1, 2023
Disclosures: Ohya reports having financial relationships with AbbVie, Eli Lilly Japan K.K., Fam Pharma, Kao, and Maruho Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co. Ltd., Pfizer, Pola Pharma Inc., Sanofi K.K., Sinopharm, Taiho Pharmaceutical Co. Ltd., Thermo Fisher Scientific, and Torii Pharmaceutical Co. Ltd. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Key takeaways: Children and adolescents with more severe atopic dermatitis had worse quality of life than those with mild disease. Hospitalizations, school absences and comorbidities all increased with disease severity. Greater atopic dermatitis severity correlated with greater disease burden in children and adolescents in Japan, according to a study. “Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition characterized by symmetrically distributed pruritic dermatitis that usually appears during infancy/childhood,” Yukihiro Ohya, MD, PhD, of the allergy center at the National Center for Child Health and Development in Tokyo, and colleagues wrote. “AD in childhood/adolescence is associated with atopic comorbidities and significant patient burden, including reduced health-related quality of life (HRQoL).” Greater atopic dermatitis severity correlated with greater disease burden in children and adolescents in Japan. Image: Adobe Stock. Pediatric populations across several countries were included in the real-world Epidemiology of Children with Atopic Dermatitis reporting on their Experience (EPI-CARE) study; however, this analysis focused on those in the study from Japan. Patients aged 6 months to 17 years were included in the survey, which consisted of a 30-minute questionnaire to be completed by caregivers or patients. The survey included demographic data, severity evaluations and AD impact on disease burden. Of 5,702 Japanese patients in the EPI-CARE database, 10.7% were diagnosed with AD, with 63.3% having clear or mild disease, 32.5% having moderate disease and 4.4% having severe disease. In all age groups, those with higher disease severity had increased symptom severity, number of flares and comorbidities , the most common being hay fever, allergic rhinitis, asthma and seasonal allergies. Greater disease severity was also linked to increased health care utilization and more absences from school, in addition to worse HRQoL. ED visits requiring hospitalization in the 12 months preceding the study were 2.9% in those with mild disease, 9.2% in those with moderate disease and 20.5% in those with severe disease. School absences were approximately three times higher in those with moderate or severe disease compared with those with mild disease. Quality of life, as measured by the HRQoL, was worse for all patients with more severe disease , but in children aged 6 to 12 years it was particularly worse, according to the study. “This population-based study of Japanese pediatric patients aged 6 months to [younger than] 18 years describes the comprehensive AD burden of patients with moderate/severe forms of the disease and highlights the medical need for safe treatments offering long-term disease control,” the authors wrote. Read more about
Mitsubishi Tanabe Pharma Investments
1 Investments
Mitsubishi Tanabe Pharma has made 1 investments. Their latest investment was in EditForce as part of their Milestone Payment on July 7, 2022.

Mitsubishi Tanabe Pharma Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
7/5/2022 | Milestone Payment | EditForce | $146M | Yes | 1 |
Date | 7/5/2022 |
---|---|
Round | Milestone Payment |
Company | EditForce |
Amount | $146M |
New? | Yes |
Co-Investors | |
Sources | 1 |
Mitsubishi Tanabe Pharma Acquisitions
2 Acquisitions
Mitsubishi Tanabe Pharma acquired 2 companies. Their latest acquisition was NeuroDerm on October 18, 2017.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
10/18/2017 | Other | $20.5M | Acq - P2P | 11 | ||
9/18/2013 | Other Venture Capital |
Date | 10/18/2017 | 9/18/2013 |
---|---|---|
Investment Stage | Other | Other Venture Capital |
Companies | ||
Valuation | ||
Total Funding | $20.5M | |
Note | Acq - P2P | |
Sources | 11 |
Mitsubishi Tanabe Pharma Partners & Customers
10 Partners and customers
Mitsubishi Tanabe Pharma has 10 strategic partners and customers. Mitsubishi Tanabe Pharma recently partnered with HitGen on February 2, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
2/25/2022 | Partner | China | In December 2018 , HitGen Inc. and MTPC entered into a drug discovery research collaboration to identify novel small molecule hits for multiple targets of interest . | 3 | |
1/18/2022 | Licensor | Switzerland | `` MTPC is delighted to collaborate with ADC Therapeutics SA , a leader in the field of antibody drug conjugates , to develop and commercialize ZYNLONTA in Japan , '' said Hiroaki Ueno , PhD , Chief Executive Officer of Mitsubishi Tanabe Pharma Corporation . | 6 | |
10/25/2021 | Licensor | United States | In Europe , Russia and Turkey , Janssen Biotech , Inc. licenses distribution rights to REMICADE to Schering-Plough Company , a subsidiary of Merck & Co , Inc. . | 1 | |
11/5/2020 | Licensor | ||||
8/18/2020 | Partner |
Date | 2/25/2022 | 1/18/2022 | 10/25/2021 | 11/5/2020 | 8/18/2020 |
---|---|---|---|---|---|
Type | Partner | Licensor | Licensor | Licensor | Partner |
Business Partner | |||||
Country | China | Switzerland | United States | ||
News Snippet | In December 2018 , HitGen Inc. and MTPC entered into a drug discovery research collaboration to identify novel small molecule hits for multiple targets of interest . | `` MTPC is delighted to collaborate with ADC Therapeutics SA , a leader in the field of antibody drug conjugates , to develop and commercialize ZYNLONTA in Japan , '' said Hiroaki Ueno , PhD , Chief Executive Officer of Mitsubishi Tanabe Pharma Corporation . | In Europe , Russia and Turkey , Janssen Biotech , Inc. licenses distribution rights to REMICADE to Schering-Plough Company , a subsidiary of Merck & Co , Inc. . | ||
Sources | 3 | 6 | 1 |
Mitsubishi Tanabe Pharma Team
2 Team Members
Mitsubishi Tanabe Pharma has 2 team members, including current President, Michihiro Tsuchiya.
Name | Work History | Title | Status |
---|---|---|---|
Michihiro Tsuchiya | President | Current | |
Name | Michihiro Tsuchiya | |
---|---|---|
Work History | ||
Title | President | |
Status | Current |